

## KEY FACTS

**CHAIRMAN,  
CHIEF EXECUTIVE OFFICER  
& PRESIDENT:**  
Howard Solomon

**CHIEF COMMERCIAL OFFICER  
& EXECUTIVE PRESIDENT:**  
Elaine Hochberg

**CHIEF FINANCIAL OFFICER & EVP,  
FINANCE & ADMINISTRATION:**  
Francis I. Perier, Jr.

**PRESIDENT, FOREST  
RESEARCH INSTITUTE &  
SVP, RESEARCH & DEVELOPMENT:**  
Marco Taglietti, M.D.

**SVP, CORPORATE DEVELOPMENT  
& STRATEGIC PLANNING:**  
David Solomon

**YEAR FOUNDED:**  
1954 (incorporated 1956)

**TOTAL EMPLOYEES (GLOBAL):**  
Approximately 5,600

**U.S. SALES FORCE:**  
Approximately 3,300

**FOREST RESEARCH INSTITUTE:**  
Approximately 1,000

**STOCK EXCHANGE LISTING:**  
New York Stock Exchange (FRX)

**WEBSITE:**  
[www.FRX.com](http://www.FRX.com)

## COMPANY

Forest Laboratories offers prescription medications with the aim of having a meaningful impact on people's lives. Our quest to deliver quality products is driven by entrepreneurial spirit, a commitment to integrity, and deep respect for people and community.

## BUSINESS MODEL

Forest Laboratories partners with pharmaceutical and biotech companies worldwide to develop its marketed products, licensing or acquiring promising new products from innovative companies at virtually every stage of development. Forest conducts rigorous scientific investigation of its drugs, and executes focused marketing and sales initiatives to firmly establish its products in the marketplace.

## PRINCIPAL BRANDS

Forest Laboratories' growing portfolio of key products includes (in alphabetical order):

**Bystolic**   
(nebivolol) tablets  
2.5 mg • 5 mg • 10 mg • 20 mg

**Savella**   
milnacipran HCl  
12.5 mg, 25 mg, 50 mg, 100 mg tablets

**Daliresp**   
(roflumilast) tablets  
500 mcg

**Teflaro**   
(ceftaroline fosamil) for injection  
600 mg • 400 mg

**Lexapro**   
escitalopram oxalate  
10mg, 20mg, and 40mg Tablets

**Viibryd**   
vilazodone HCl  
10 mg, 20 mg, 40 mg tablets

**Namenda**   
(memantine HCl) tablets  
5 mg and 10 mg

For more information, including Boxed Warnings for **Lexapro**, **Savella**, and **Viibryd**, and to view full Prescribing Information, please visit [www.frx.com/products](http://www.frx.com/products).

## LOCATIONS

### CORPORATE HEADQUARTERS:

909 Third Avenue  
New York, NY 10022  
1- 800-947-5227 *Toll-free*  
1-212-421-7850  
[www.FRX.com](http://www.FRX.com)

### IN THE US:

Cincinnati, OH  
Commack, NY  
Farmingdale, NY  
Hauppauge, NY  
Jersey City, NJ  
Oakland, CA  
St. Louis, MO

### IN EUROPE:

Ireland  
United Kingdom  
Paris, France

## PIPELINE

Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories. Forest's current product pipeline includes therapies in all stages of development and across a wide range of therapeutic areas. The following is a partial listing of our compounds in development (in alphabetical order) and the targeted therapeutic area:

- **Acidinium** for chronic obstructive pulmonary disease (COPD)
- **Acidinium + formoterol** for COPD
- **Apadenoson** for radionuclide myocardial perfusion imaging
- **Azimilide** for the reduction of ventricular arrhythmias
- **Cariprazine** for bipolar mania, schizophrenia, adjunctive therapy for major depressive disorder, and bipolar depression
- **Ceftaroline + avibactam** for hospital infections
- **Ceftazidime + avibactam** for hospital infections
- **GK1-399** for Type II diabetes
- **GRT 6005** and **GRT 6006** for pain management
- **LAS 100977** for asthma and COPD
- **Levomilnacipran (F2695)** for major depressive disorder
- **Linaclotide** for chronic constipation and constipation-predominant irritable bowel syndrome

## SALES AND MARKETING

In the United States, Forest markets its prescription products through its subsidiary, Forest Pharmaceuticals, Inc., and several dedicated primary and specialty sales teams. In the United Kingdom, Ireland, and certain export markets, Forest products are marketed directly by subsidiaries Forest Laboratories UK, Ltd, and Forest Tosara Ltd.

## FINANCIALS

For the fiscal year ending March 31, 2011, Forest reported \$4,419,700,000 in net revenue, a 5.4% increase from the previous year; \$1,046,770,000 in net income; and diluted earnings per share of \$3.59.

## BUSINESS UPDATE

Fiscal year 2011 was a busy and successful one for the Company. The year was highlighted by solid financial performance; three important product approvals including the approval and launch of **Teflaro**; the successful completion of additional Phase III clinical trials for acidinium and linaclotide; the completion of four new business development agreements that will provide additional future growth opportunities; and the announcement of the acquisition of Clinical Data, Inc. that brings an exciting product, **Vibryd**, and an additional promising development pipeline to Forest.

During the fiscal year, Forest and partner Merz Pharmaceuticals announced FDA approval for **Namenda XR**. Forest also announced the FDA approval of **Teflaro** and the approval of **Daliresp**.

**CONTACT**

**INVESTORS & MEDIA:**

Frank J. Murdolo  
 Vice President, Investor Relations  
 Forest Laboratories, Inc.  
 1-212-224-6714  
 Frank.Murdolo@frx.com

**PHYSICIANS:**

Medical Information and  
 Communication  
 1-800-678-1605, ext. 66297

**BUSINESS UPDATE (CONTINUED)**


Forest and partner Almirall reported positive topline results from the Phase III clinical trial for acilidium in the treatment of COPD and filed the New Drug Application (NDA) with the FDA in mid-Calendar Year 2011. In conjunction with Ironwood Pharmaceuticals, Forest reported positive topline results from the Phase III clinical trial of linaclotide in the treatment of chronic constipation and filed the NDA in Q3 CY2011.

Forest entered into a licensing agreement with TransTech Pharma for the development and commercialization of glucokinase activators, a class of investigational glucose-lowering agents in development for the treatment of diabetes. Forest completed two business development transactions with Gruenthal, the first for a licensing agreement for the development and commercialization of an analgesic being investigated for the treatment of moderate to severe chronic pain, currently in Phase I development, and the second transaction for the acquisition of Gruenthal's cystic fibrosis franchise in Europe.

In April 2011, Forest announced the completion of its acquisition of Clinical Data, Inc. This transaction allows the Company to leverage its existing presence in a particular therapeutic category through the launch of **Viibryd**. **Viibryd** was approved by the FDA on January 21, 2011.

Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC entered into an asset purchase agreement, pursuant to which Forest acquired worldwide rights to azimilide, an investigational antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

Looking forward, the Company plans to launch three new products and file an additional NDA with the FDA during CY2011, and continues to advance its earlier-stage products in the development pipeline.



Figures represent amounts in thousands of dollars